Hulme, CH ORCID: https://orcid.org/0000-0002-4961-2185, Perry, J ORCID: https://orcid.org/0000-0002-5953-1389, McCarthy, HS ORCID: https://orcid.org/0000-0001-9534-7565, Wright, KT ORCID: https://orcid.org/0000-0001-8842-5908, Snow, M, Mennan, C ORCID: https://orcid.org/0000-0001-9532-753X and Roberts, S ORCID: https://orcid.org/0000-0003-1835-327X Cell Therapy for Cartilage Repair.

[img] Text
Accepted_Cell Therapy for Cartilage Repair.docx - Accepted Version

Download (5MB)
[img]
Preview
Text
etls-2021-0015c.pdf - Published Version

Download (8MB) | Preview

Abstract

Regenerative medicine, using cells as therapeutic agents for the repair or regeneration of tissues and organs, offers great hope for the future of medicine. Cell therapy for treating defects in articular cartilage has been an exemplar of translating this technology to the clinic, but it is not without its challenges. These include applying regulations, which were designed for pharmaceutical agents, to living cells. In addition, using autologous cells as the therapeutic agent brings additional costs and logistical challenges compared with using allogeneic cells. The main cell types used in treating chondral or osteochondral defects in joints to date are chondrocytes and mesenchymal stromal cells derived from various sources such as bone marrow, adipose tissue or umbilical cord. This review discusses some of their biology and pre-clinical studies before describing the most pertinent clinical trials in this area.

Item Type: Article
Subjects: R Medicine > R Medicine (General)
R Medicine > R Medicine (General) > R735 Medical education. Medical schools. Research
R Medicine > RA Public aspects of medicine
R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Depositing User: Symplectic
Date Deposited: 03 Sep 2021 14:59
Last Modified: 03 Sep 2021 14:59
URI: https://eprints.keele.ac.uk/id/eprint/9905

Actions (login required)

View Item View Item